These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32690108)

  • 1. Cytokine profile and nitric oxide levels in peritoneal macrophages of BALB/c mice exposed to the fucose-mannose ligand of Leishmania infantum combined with glycyrrhizin.
    Namdar Ahmadabad H; Shafiei R; Hatam GR; Zolfaghari Emameh R; Aspatwar A
    Parasit Vectors; 2020 Jul; 13(1):363. PubMed ID: 32690108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine profile and nitric oxide levels in macrophages exposed to Leishmania infantum FML.
    Reza S; Hasan NA; Maryam NF; Fahimeh B; Ghahremani A; GholamReza H; Amin GM
    Exp Parasitol; 2019 Aug; 203():1-7. PubMed ID: 31128104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine Profile of Leishmania Infantum Fucose-Mannose Ligand in Vaccinated Dogs in the Northwest of Iran.
    Mohammadi-Ghalehbin B; Hatam G; Sarkari B; Mohebali M; Zarei Z; Bohlooli S
    Iran J Immunol; 2017 Dec; 14(4):293-305. PubMed ID: 29276182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haemolytic activities of plant saponins and adjuvants. Effect of Periandra mediterranea saponin on the humoral response to the FML antigen of Leishmania donovani.
    Santos WR; Bernardo RR; Peçanha LM; Palatnik M; Parente JP; Palatnik de Sousa CB
    Vaccine; 1997 Jun; 15(9):1024-9. PubMed ID: 9261952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A chimeric vaccine combined with adjuvant system induces immunogenicity and protection against visceral leishmaniasis in BALB/c mice.
    Ostolin TLVDP; Gusmão MR; Mathias FAS; Cardoso JMO; Roatt BM; Aguiar-Soares RDO; Ruiz JC; Resende DM; de Brito RCF; Reis AB
    Vaccine; 2021 May; 39(20):2755-2763. PubMed ID: 33875268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leishmania infantum FML pulsed-dendritic cells induce a protective immune response in murine visceral leishmaniasis.
    Foroughi-Parvar F; Hatam GR; Sarkari B; Kamali-Sarvestani E
    Immunotherapy; 2015; 7(1):3-12. PubMed ID: 25572475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble
    Margaroni M; Agallou M; Athanasiou E; Kammona O; Kiparissides C; Gaitanaki C; Karagouni E
    Int J Nanomedicine; 2017; 12():6169-6184. PubMed ID: 28883727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
    Datta N; Mukherjee S; Das L; Das PK
    Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two biochemically distinct lipophosphoglycans from Leishmania braziliensis and Leishmania infantum trigger different innate immune responses in murine macrophages.
    Ibraim IC; de Assis RR; Pessoa NL; Campos MA; Melo MN; Turco SJ; Soares RP
    Parasit Vectors; 2013 Mar; 6():54. PubMed ID: 23497381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of the immunomodulatory effects of spore polysaccharides and broken spore polysaccharides isolated from Ganoderma lucidum on murine splenic lymphocytes and peritoneal macrophages in vitro].
    Wang PY; Wang SZ; Lin SQ; Lin ZB
    Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Dec; 37(6):569-74. PubMed ID: 16378103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining Killed Vaccine Candidate with Different Adjuvants to Determine Prophylactic Potential against Leishmaniasis.
    Kelleci K; Allahverdiyev A; Bağırova M; Ihlamur M; Abamor EŞ
    Acta Parasitol; 2024 Sep; 69(3):1613-1620. PubMed ID: 39164549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Leishmania infantum FML-ELISA for the detection of symptomatic and asymptomatic canine visceral leishmaniasis in an endemic area of Iran.
    Mohammadi-Ghalehbin B; Hatam GR; Sarkari B; Mohebali M; Zare Z; Jaberipour M; Bohlouli S
    Iran J Immunol; 2011 Dec; 8(4):244-50. PubMed ID: 22201622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canine Leishmania vaccines: still a long way to go.
    Gradoni L
    Vet Parasitol; 2015 Feb; 208(1-2):94-100. PubMed ID: 25620293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental murine Leishmania donovani infection: immunoprotection by the fucose-mannose ligand (FML).
    Palatnik-de-Sousa CB; Paraguai-de-Souza E; Gomes EM; Borojevic R
    Braz J Med Biol Res; 1994 Feb; 27(2):547-51. PubMed ID: 8081280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Insights on the Adjuvant Properties of the
    Koutsoni OS; Barhoumi M; Guizani I; Dotsika E
    J Immunol Res; 2019; 2019():9124326. PubMed ID: 31183394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pam3CSK4 adjuvant given intranasally boosts anti-Leishmania immunogenicity but not protective immune responses conferred by LaAg vaccine against visceral leishmaniasis.
    Salgado CL; Dias EL; Stringari LL; Covre LP; Dietze R; Lima Pereira FE; de Matos Guedes HL; Rossi-Bergmann B; Gomes DCO
    Microbes Infect; 2019; 21(7):328-335. PubMed ID: 30817996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycyrrhizic acid suppresses Cox-2-mediated anti-inflammatory responses during Leishmania donovani infection.
    Bhattacharjee S; Bhattacharjee A; Majumder S; Majumdar SB; Majumdar S
    J Antimicrob Chemother; 2012 Aug; 67(8):1905-14. PubMed ID: 22589456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of adjuvant activity of fractions derived from Agaricus blazei, when in association with the recombinant LiHyp1 protein, to protect against visceral leishmaniasis.
    de Jesus Pereira NC; Régis WC; Costa LE; de Oliveira JS; da Silva AG; Martins VT; Duarte MC; de Souza JR; Lage PS; Schneider MS; Melo MN; Soto M; Soares SA; Tavares CA; Chávez-Fumagalli MA; Coelho EA
    Exp Parasitol; 2015 Jun; 153():180-90. PubMed ID: 25845753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis.
    Oliveira-da-Silva JA; Machado AS; Ramos FF; Tavares GSV; Lage DP; Mendonça DVC; Pereira IAG; Santos TTO; Martins VT; Carvalho LM; Freitas CS; Ludolf F; Reis TAR; Bandeira RS; Silva AM; Costa LE; Oliveira JS; Duarte MC; Roatt BM; Teixeira AL; Coelho EAF
    Cell Immunol; 2020 Oct; 356():104194. PubMed ID: 32827943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
    Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.